Related Experiment Videos
The role of C-reactive protein in cardiovascular disease risk
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. maalbert@bics.bwh.harvard.edu
Insights
C-reactive protein (CRP) is a strong inflammation marker for coronary artery disease (CAD). While widely used, its exact clinical role and ability to improve cardiovascular risk prediction beyond traditional factors require further definition.
Area of Science:
- Biomedical research
- Cardiovascular medicine
- Inflammation markers
Background:
- C-reactive protein (CRP) is increasingly recognized as a key inflammation marker in coronary artery disease (CAD).
- Inflammation is a critical factor in the development of atherosclerosis.
- Hospital labs widely measure CRP, but clinical application needs further clarification.
Purpose of the Study:
- To evaluate the role of C-reactive protein (CRP) as an inflammation marker in coronary artery disease (CAD).
- To assess the predictive value of CRP for cardiovascular disease risk.
- To determine if CRP enhances risk stratification beyond established CAD risk factors.
Main Methods:
- Review of medical literature implicating CRP in CAD pathogenesis.
- Analysis of plasma-based markers for cardiovascular disease risk prediction.
- Comparison of CRP's predictive power against traditional CAD risk factors.
Main Results:
- CRP is the strongest plasma-based marker for predicting cardiovascular disease risk in both men and women.
- Existing data strongly implicates CRP as a marker of inflammation in CAD.
- The extent to which CRP improves risk stratification beyond traditional factors is still under investigation.
Conclusions:
- C-reactive protein (CRP) is a significant inflammation marker associated with coronary artery disease (CAD).
- CRP demonstrates strong predictive value for cardiovascular disease risk.
- Further research is needed to define the clinical utility of CRP in risk stratification for CAD.
Abstract:
Over the past few years, a flurry of data in the medical literature has strongly implicated C-reactive protein (CRP) as a marker of inflammation in coronary artery disease (CAD). Recognizing the likely integral role that inflammation plays in the pathogenesis of atherosclerosis, many hospital laboratories have tests to measure CRP concentration in the clinical setting. However, the clinical use of these tests still need definition. To date, of the plasma-based markers investigated, CRP provides the strongest risk prediction for cardiovascular disease in men and women. Questions remain regarding the degree to which CRP can improve risk stratification beyond that of the traditional risk factors of CAD.